Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

7.7%

1 terminated/withdrawn out of 13 trials

Success Rate

92.3%

+5.8% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

6 of 12 completed trials have results

Key Signals

6 with results

Enrollment Performance

Analytics

Phase 1
7(53.8%)
Phase 2
6(46.2%)
13Total
Phase 1(7)
Phase 2(6)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (13)

Showing 13 of 13 trials
NCT03285178Phase 2Completed

A Study of the Effect of IW-1701 (Olinciguat), a Stimulator of Soluble Guanylate Cyclase (sGC), on Patients With Sickle Cell Disease (SCD)

Role: lead

NCT03254485Phase 2Completed

A Study of the Effect of IW-1973 on the Exercise Capacity of Patients With Heart Failure With Preserved Ejection Fraction (HFpEF)

Role: collaborator

NCT03217591Phase 2Completed

A Study to Evaluate the Soluble Guanylate Cyclase (sGC) Stimulator IW-1973 in Diabetic Nephropathy / Diabetic Kidney Disease as Measured by Albuminuria

Role: collaborator

NCT02931565Phase 2Terminated

Study of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Type I or II Achalasia

Role: lead

NCT03091920Phase 2Completed

Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC) in Patients With Stable Type 2 Diabetes and Hypertension

Role: lead

NCT02906579Phase 2Completed

A Phase 2 Trial of IW-1973, A Stimulator of Soluble Guanylate Cyclase (sGC), in Patients With Stable Type 2 Diabetes and Hypertension

Role: lead

NCT03892499Phase 1Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator, Olinciguat (IW-1701), in Healthy Volunteers

Role: lead

NCT03818295Phase 1Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Praliciguat in Healthy Male Volunteers

Role: lead

NCT02792998Phase 1Completed

A Trial of IW-1701, A Stimulator of Soluble Guanylate Cyclase (sGC), in Healthy Subjects

Role: lead

NCT03499106Phase 1Completed

A Trial to Evaluate the Effect of Itraconazole (ITZ), a CYP3A4 Inhibitor, on the Pharmacokinetics of Praliciguat (IW-1973) in Healthy Volunteers

Role: lead

NCT03795519Phase 1Completed

A Trial to Study the Absorption, Metabolism, and Excretion of [14C]-Olinciguat in Healthy Male Volunteers

Role: lead

NCT02616861Phase 1Completed

Trial of IW-1973 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Role: lead

NCT02572349Phase 1Completed

Trial of IW-1701 (A Stimulator of Soluble Guanylate Cyclase (sGC)) in Healthy Volunteers

Role: lead

All 13 trials loaded